Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer plans to buy its pain partner in a deal valued at $56 million, including the 11% of shares the big pharma already owns in Icagen.